Stephen J. Petti

Hibernaid, Inc. develops and manufactures drugs. Its compound HBN-1 is used for resuscitated post-cardiac arrest patients as well as for the treatment of stroke, traumatic brain injury, spinal cord injury, and other acute critical care indications. The company was founded by Stephen J. Petti and Laurence M. Katz and is headquartered in Troy, NY.

Blue Note Pharmaceuticals is a privately held biopharmaceutical company with offices in Troy, New York and Amsterdam, The Netherlands. Blue Note's mission is to acquire, advance, develop, partner and commercialize carefully selected undervalued drug development candidates with the potential to more effectively treat or help prevent major medical conditions affecting society. The Company's lead development project is BNP 32,762, a pharmacokinetically unique calcium channel blocker (CCB) being evaluated in late-stage clinical trials for the treatment of hypertension and chronic stable angina. Blue Note is also evaluating various products that would combine BNP 32,762 with other commonly accepted antihypertensive drugs such as ACE inhibitors, Angiotensin Receptor Blockers (ARBs) and diuretics. The Company's cardiovascular-oriented pipeline also includes an early-stage program for the prevention of Deep Vein Thrombosis (DVT) and for the treatment of a number of other important cardiovascular indications.

VYV, Inc. designs, engineers, and manufactures germ-killing LED technology for an expanding range of commercial and residential applications. The company was founded by Colleen A. Costello and James Peterson and is headquartered in Troy, NY.

Barnett International provides consulting services and conducts education training programs. It also provides services for companies in the pharmaceutical and biotechnology industries. The firm’s services include outsourcing management, clinical training, technological analysis and implementation. The company was founded in 1979 and is headquartered in Centreville, VA.

DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ.

Part of Neurobiological Technologies, Inc., Empire Pharmaceuticals, Inc. develops late-stage perfusion therapy for use in the treatment of acute ischemic stroke. The company is based in Newbury Park, CA. The company was founded by Stephen J. Petti, David E. Levy. Empire Pharmaceuticals was acquired by Neurobiological Technologies, Inc. on July 15, 2004 for $22.91 million.

American Heart Association, Inc. operates a voluntary health organization funded by private contributions. The organization offers services for coronary heart diseases and strokes, high blood cholesterol & physical inactivity, obesity, and diabetes. The company was founded in 1924 and is headquartered in Dallas, TX.